Efficacy and safety of methotrexate versus placebo as add-on therapy to H1 antihistamines for patients with difficult-to-treat chronic spontaneous urticaria: A randomized, controlled trial - 12/11/19
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Dr Leducq, Dr Samimi, and Dr Maruani contributed to this work equally. |
|
Funding sources: Supported by the French Ministry of Social Affairs and Health (French National Programme of Clinical Research 2009). |
|
Conflicts of interest: Pr Samimi has received speaking fees for an educational program from BMS, Janssen, Acthelion, and AbbVie. Dr Soria has received honoraria for serving as a speaker, an advisor, and a consultant from Novartis. Dr Amsler has received honoraria for serving as a speaker and an advisor from Novartis. Pr Staumont-Sallé has received fees for serving as an advisor or a speaker from Janssen, Novartis, Sanofi, Pfizer, AbbVie, and Lilly and has received research funding for serving as a principal investigator from Galderma, Leo Pharma, Novartis, and Lilly. Dr Wierzbicka-Hainaut has received honoraria for serving as an advisor for Novartis and Sanofi. Dr Raison-Peyron has received honoraria for serving as a speaker and principal investigator from Novartis and has received equipment from Novartis. Dr Leducq, Dr Bernier, Dr Gabison, Pr Chosidow, Dr Bénéton, Dr Bara, Dr Grange-Prunier, Dr Brenaut, Dr Droitcourt, Dr Bourgoin, Dr Cornillier, Pr Machet, Pr Giraudeau, Dr Caille, and Pr Maruani have no conflicts of interest to disclose. |
|
Previously presented at the 24th World Congress of Dermatology on June 10-15, 2019, in Milan, Italy. |
|
Reprints not available from the authors. |
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?